Compare BIIB & LUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | LUV |
|---|---|---|
| Founded | 1978 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 17.6B |
| IPO Year | 1991 | N/A |
| Metric | BIIB | LUV |
|---|---|---|
| Price | $181.61 | $37.98 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 13 |
| Target Price | ★ $176.48 | $34.31 |
| AVG Volume (30 Days) | 1.9M | ★ 7.3M |
| Earning Date | 10-30-2025 | 10-22-2025 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.97 | 0.67 |
| Revenue | $10,065,900,000.00 | ★ $27,551,000,000.00 |
| Revenue This Year | $3.61 | $3.65 |
| Revenue Next Year | N/A | $7.79 |
| P/E Ratio | ★ $16.52 | $56.92 |
| Revenue Growth | ★ 4.77 | 0.64 |
| 52 Week Low | $110.04 | $23.82 |
| 52 Week High | $185.17 | $38.17 |
| Indicator | BIIB | LUV |
|---|---|---|
| Relative Strength Index (RSI) | 72.92 | 74.23 |
| Support Level | $174.53 | $35.12 |
| Resistance Level | $182.94 | $35.39 |
| Average True Range (ATR) | 5.22 | 1.23 |
| MACD | 0.25 | 0.45 |
| Stochastic Oscillator | 83.54 | 95.72 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Southwest Airlines is the largest domestic air carrier in the United States by passengers boarded. Southwest operates nearly 800 aircraft in an all-Boeing 737 fleet. Despite offering some longer routes and a few perks for business travelers, the airline predominantly specializes in short-haul, leisure flights operated in a single, open-seating cabin configuration in a point-to-point network. In late 2025, Southwest will modify its cabins to offer some rows with extra legroom and will update its ticketing process and merchandising to offer assigned seats and more fare categories, including a basic economy class that will more directly compete with other airlines' offerings and appear for the first time in travel aggregators' search results.